Skip to Main Content
Table 3—

Follow-up characteristics of HCV and non-HCV patients

CharacteristicHCV subjectsNon-HCV subjectsP
n 24 288 — 
Diastolic blood pressure on follow-up (mmHg) 84.7 ± 2.3 79.6 ± 0.58 0.0154 
Weighted mean follow-up LDL (mg/dl) 89.6 ± 14.1 (n = 9) 124.2 ± 3.54 (n = 148) 0.0201 
Weighted mean follow-up total cholesterol (mg/dl) 166.8 ± 15.6 (n = 11) 210.8 ± 4.23 (n = 170) 0.0108 
Weighted mean glycosylated hemoglobin (%) 9.43 ± 1.1 (n = 10) 9.94 ± 0.28 (n = 139) 0.646 
Renin angiotensin system inhibitor (ever) 19/23 (82.6) 242/270 (89.6) 0.295 
Mean number of blood pressure medications over follow-up 3.11 ± 0.25 3.09 ± 0.09 0.959 
Follow-up time (months) 19.5 ± 2.6 25.2 ± 1.5 0.269 
CharacteristicHCV subjectsNon-HCV subjectsP
n 24 288 — 
Diastolic blood pressure on follow-up (mmHg) 84.7 ± 2.3 79.6 ± 0.58 0.0154 
Weighted mean follow-up LDL (mg/dl) 89.6 ± 14.1 (n = 9) 124.2 ± 3.54 (n = 148) 0.0201 
Weighted mean follow-up total cholesterol (mg/dl) 166.8 ± 15.6 (n = 11) 210.8 ± 4.23 (n = 170) 0.0108 
Weighted mean glycosylated hemoglobin (%) 9.43 ± 1.1 (n = 10) 9.94 ± 0.28 (n = 139) 0.646 
Renin angiotensin system inhibitor (ever) 19/23 (82.6) 242/270 (89.6) 0.295 
Mean number of blood pressure medications over follow-up 3.11 ± 0.25 3.09 ± 0.09 0.959 
Follow-up time (months) 19.5 ± 2.6 25.2 ± 1.5 0.269 

Data are means ± SE or n (%).

Close Modal

or Create an Account

Close Modal
Close Modal